High Incidence of CMV Reactivation after Haploidentical Donor Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide, and Its Impact on Transplant Outcomes

Monzr M. Al Malki(City of Hope), Ryotaro Nakamura(City Of Hope National Medical Center), Stephen J. Forman(City Of Hope National Medical Center), Sanjeet Dadwal(City Of Hope National Medical Center), Ibrahim Aldoss(City of Hope), Joseph Rosenthal(City Of Hope National Medical Center), David Senitzer(City of Hope), Dongyun Yang(City of Hope), Ketevan Gendzekhadze(City Of Hope National Medical Center), John A. Zaia(City Of Hope National Medical Center), Thai M. Cao(City of Hope), Margaret O’Donnell(City Of Hope National Medical Center), Pablo Parker(City Of Hope National Medical Center), Auayporn Nademanee(City Of Hope National Medical Center), Don J. Diamond(City of Hope), David S. Snyder(City Of Hope National Medical Center), Sally Mokhtari(City of Hope)
Blood
December 8, 2017
10.1182/blood.v130.suppl_1.4494.4494
Cited by 9

Related Papers

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k